AlzeCure changes direction for its drug candidate ACD855 within the NeuroRestore platform
AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that they will redirect the drug candidate ACD855 within the research platform NeuroRestore from cognitive dysfunction to an indication in the eye instead. This means that the ongoing Phase I clinical studies with ACD855 will be terminated and that the substance instead will be tested for one of the previously planned indications instead.ACD855 has so far proved to be safe in humans, but it exhibits a longer half-life in humans than expected, which means that the company considers it more suitable for local administration than